Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Latest "Galectin Therapeutics" News Stories

09:23 EDT 20th April 2014 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 76

Extremely Relevant

Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration

NORCROSS, Ga. and NATICK, Mass., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, and SBH Sciences, Inc., a world leader in cell-based assays to measure biological activity and developer of cytokines, growth factors, biologics and monoclonal antibodies, jointly announce the...

Relevant

Galectin raises $23.9 million

Galectin Therapeutics Inc. (NASDAQ:GALT) said on Friday that it raised $23.9 million in an at-the-market program with MLV. From Oct. 28, 2013, through Jan. 9, the company sold 2.4 million shares at an average price of $9.99. Galectin jumped $1.61 (12...

Galectin gets $23.8 million in public offering financing

Though public offering financing, Galectin gets $23,883,137. Galectin Therapeutics announced that it had sold a total of 2,391,204 shares of common stock at an average price per share of $9.99 for total gross proceeds of $23,883,137 through its at-the-market (ATM) financing vehicle. After commissions, the Company received $23,164,712 in net proceeds. The intended use of more »The post Galectin ge...

Galectin Therapeutics Supports Investigational New Drug (IND) Application for Its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma

NORCROSS, Ga., Jan. 15, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Providence Portland Medical Center filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) on December 27, 2013 to study GR-MD-02 in combination...

Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease

NORCROSS, Ga., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Patent and Trademark Office issued patent number 8,658,787 to the Company for its application titled "Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatoh...

Galectin, SBH Sciences in R&D Alliance

To develop Galectin inhibitors for oral administration

Galectin Therapeutics supports IND application for its galectin inhibitor in metastatic melanoma

Galectin Therapeutics has announced that Providence Portland Medical Center filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) on 27 December 2013 to study GR-MD-02 in combination with Yervoy (ipilimuma...

Galectin Therapeutics secures US patent for galectin inhibitor in fatty liver disease

Galectin Therapeutics has announced that the US Patent and Trademark Office issued patent number 8,658,787 to the company for its application titled ‘Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and no...

Galectin Therapeutics Receives FDA approval to proceed with Phase IB clinical trial in metastatic melanoma

Galectin Therapeutics has announced that the US Food and Drug Administration (FDA) has agreed that a Phase IB clinical trial of the galectin inhibitor GR-MD-02 in combination with Yervoy (ipilimumab) in patients with metastatic melanoma may proceed.

Galectin completes enrolment in first cohort of Phase I study of liver drug

Galectin Therapeutics has completed patient enrolment in its first cohort of a multi-centre, partially blinded Phase I trial of GR-MD-02, intended for the treatment of fatty liver disease with advanced fibrosis.

Galectin Therapeutics, SBH Sciences Inc. deal

Galectin Therapeutics Reports 2013 Financial Results

NORCROSS, Ga., March 21, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the year ended December 31, 2013. These results are included in the Company's Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commissi...

Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference

NORCROSS, Ga., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conference, to be held February 10-11, 2014, at the Waldorf Astoria Hotel in New York City. The conference is hosted by the...

Galectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop

NORCROSS, Ga., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the Nonalcoholic Steatohepatitis (NASH) Workshop hosted by JMP Securities on Thursday, February 27, 2014 in New York, NY. NASH, a progressive liver disease cause...

Galectin Therapeutics Receives US Patent for Combination Treatment for Liver Fibrosis

NORCROSS, Ga., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for patent application number 13/550,962 titled "Galactose-Pronged Polysaccharides in a Formulation for Anti-fibrot...

Galectin Therapeutics Announces Update on Financing Activities and Cash of $32.3 Million

NORCROSS, Ga., Jan. 10, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it had sold, from October 28, 2013 through January 9, 2014, a total of 2,391,204 shares of common stock at an average price per share of $9.99 for total gross proceeds of $23,883,137 throug...

Galectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference

NORCROSS, Ga., Feb. 13, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer of Galectin Therapeutics, served on a panel titled "Keeping an I on Oncology: The ASCO Immunotherapy Prev...

BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test

WALTHAM, Mass., Dec. 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company's galectin-3 blood test (analyte-specific CPT® Code 82777) at the amount of a crosswalked test (analyte-specific CPT® Code 84244) whose 20...

Trials & Filings in Brief: Jan. 15, 2014

AbbVie, Antares, Elite, Galectin, La Jolla

Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer

Trials & Filings in Brief: Jan. 13, 2014

Ampio, Galectin, Generex, Gilead, Merck, The Medicines Company

Automated VIDAS(R) Galectin-3 Assay Validated in Published Clinical Research Study

WALTHAM, Mass., Jan. 28, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, welcomed today the publication of results of a clinical research study that demonstrate and validate the analytical and clinical performance of the automated VIDAS® Galectin-3 assay that was developed by bioMérieux SA, a world leader in the field of in vitro diagnostics...

Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors

Galectin Therapeutics Executive Chairman James Czirr to Present at RedChip Emerging Growth Showcase

NORCROSS, Ga., Jan. 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that its executive chairman James Czirr will present during the RedChip Emerging Growth Showcase on Thursday, January 23, 2013 at 11:30 a.m. Eastern Standard Time. The RedChip Emerging Growth...

BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers

WALTHAM, Mass., March 10, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that galectin-3 testing has been recognized for the first time in the newly issued 2014 Indian Consensus Document on Cardiac Biomarkers published by the Cardiological Society of India. [1] The Consensus Document on Cardiac Biomarkers reviews cardiac blood tests that are available for diagnosis and m...


Search BioPortfolio:
Advertisement

News Quicklinks

Advertisement